Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized fentanyl versus saline for exertional dyspnoea in fibrotic interstitial lung disease
ACTRN12621000454875Phase 4Completed
- Sponsor
- The University of Auckland
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of fentanyl in interstitial lung disease (ILD) and pulmonary fibrosis (PF) (2 arms), sponsored by The University of Auckland. Primary endpoints: Dyspnoea intensity, Exercise endurance time and 1 more. Started Jul 2023; status: completed.
02
Drugs
fentanyl
03
Conditions
interstitial lung disease (ILD)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on ACTRN12621000454875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000454875.